<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02474212</url>
  </required_header>
  <id_info>
    <org_study_id>290115-1</org_study_id>
    <nct_id>NCT02474212</nct_id>
  </id_info>
  <brief_title>: Pharmacokinetics of Enoxaparin After Coronary Artery Bypass Graft Surgery</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tampere University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetics of the thromboprophylactic agent enoxaparin in postoperative
      cardiac surgery patients by comparing plasma anti-Xa activity when enoxaparin is administered
      either as a continuous intravenous infusion or subcutaneous bolus once daily.

      After informed consent, 80 elective on pump CABG patients with a clinical indication for
      post-operative thromboprophylaxis will be studied in the Tampere University Hospital Heart
      Central. The study will consist of two independent parts. In the first part of the study
      twenty elective CABG patients will be randomised to receive subcutaneous enoxaparin
      (Klexane®, Sanofi-Aventis) 40 mg thromboprophylaxis every 24 hours for three days. Another
      twenty patients will be randomised to receive the same dose of enoxaparin (40 mg) daily as
      continuous intravenous infusion for three days (72 hours). In the second part of the study
      twenty elective CABG patients will be randomised to receive subcutaneous enoxaparin
      (Klexane®, Sanofi-Aventis) 0,5 mg/ kg twice a day. Another twenty patients will be randomised
      to receive enoxaparin 1 mg/kg daily as continuous intravenous infusion for three days (72
      hours).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak plasma anti-FXa level</measure>
    <time_frame>At 3 hours after study drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Deep vein thrombosis</measure>
    <time_frame>On day 3</time_frame>
    <description>Reviewed by Wells score or a compression ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary embolism</measure>
    <time_frame>On day 3</time_frame>
    <description>Reviewed by Wells dichotomous or a pulmonary computerized tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>On day 3</time_frame>
    <description>Major bleeding: fall in haemoglobin level of at least 20 g/l or require transfusion of 2 or more units of packed cells Minor bleeding: any other bleeding episode</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Pulmonary Embolism</condition>
  <condition>Thromboprophylaxis</condition>
  <arm_group>
    <arm_group_label>Enoxaparin 40 mg s.c.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous enoxaparin (Klexane®, Sanofi-Aventis) 40 mg thromboprophylaxis every 24 hours for three days (72 hours)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin 40 mg i.v.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enoxaparin thromboprophylaxis (40 mg) daily as continuous intravenous infusion for three days (72 hours)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin 0.5 mg/kg s.c.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous enoxaparin (Klexane®, Sanofi-Aventis) 0.5 mg/kg thromboprophylaxis twice a day for three days (72 hours)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin 1 mg/kg i.v.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enoxaparin thromboprophylaxis 1 mg/kg daily as continuous intravenous infusion for three days (72 hours)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <arm_group_label>Enoxaparin 40 mg s.c.</arm_group_label>
    <arm_group_label>Enoxaparin 40 mg i.v.</arm_group_label>
    <arm_group_label>Enoxaparin 0.5 mg/kg s.c.</arm_group_label>
    <arm_group_label>Enoxaparin 1 mg/kg i.v.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI between 18-30 kg/m2

          -  Elective on-pump CABG operation

          -  Indication for post-operative pharmacological thromboprophylaxis

          -  Written informed consent obtained from the patient or his/her legal representative.

        Exclusion Criteria:

          -  Other indications for anticoagulant therapy than thromboprophylaxis

          -  Known heparin induced thrombocytopenia (HIT), or hypersensitivity to enoxaparin or
             heparin

          -  Any long-term anticoagulant medication, expect low-dose aspirin

          -  Major bleeding within the last week unless definitively treated

          -  Blood platelet count &lt;20, P-TT &lt;20 % or INR &gt;1.7

          -  GFR less than 30 ml/min/1.73 m2 estimated from serum creatinine by applying
             Cockcroft-Gault equation 13 or chronic dialysis

          -  Known HIV, HBV, or HCV infection

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <state>Pirkanmaa</state>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annukka Vahtera, MD</last_name>
      <phone>+358331169509</phone>
      <email>annukka.vahtera@pshp.fi</email>
    </contact>
    <contact_backup>
      <last_name>Kati Järvelä, PhD</last_name>
      <phone>+3583311 64 869</phone>
      <email>kati.jarvela@sydansairaala.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Annukka Vahtera, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kati Järvelä, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juha Hautalahti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Parviainen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2015</study_first_submitted>
  <study_first_submitted_qc>June 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2015</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tampere University Hospital</investigator_affiliation>
    <investigator_full_name>Annukka Vahtera</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Venous thromboembolism</keyword>
  <keyword>pulmonary embolism</keyword>
  <keyword>thromboprophylaxis</keyword>
  <keyword>anticoagulant</keyword>
  <keyword>anti-FXa</keyword>
  <keyword>low-molecular weight heparin</keyword>
  <keyword>enoxaparin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

